Next 10 |
home / stock / xlo / xlo articles
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quar...
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 15 points on Thursday. The Dow traded up 0.06% to 39,7...
Xilio Therapeutics Inc (NASDAQ:XLO) shares are surging as the company announced an exclusive license agreement with Gilead Sciences Inc&n...
U.S. stocks traded slightly higher midway through trading, with the S&P 500 gaining around 0.1% on Thursday. The Dow traded up 0.06% to 39,785....
U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow tra...
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and X...
WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and ...
WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and ...
News, Short Squeeze, Breakout and More Instantly...
Xilio Therapeutics Inc. Company Name:
XLO Stock Symbol:
NASDAQ Market:
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quar...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and ...